Duffy M J, O'Siorain L, Waldron B, Smith C
Clin Chem. 1986 Oct;32(10):1972-4.
Our aim here was to compare a new enzyme immunoassay for estradiol receptors (ER) in breast cancer with a standard assay involving radiolabeled estradiol. A significant correlation was obtained between the standard binding assay and immunoassay (rs = 0.945, p less than 0.001, n = 100). Immunoreactive ER were also found in endometrial carcinomas but not in lung carcinomas, malignant melanomas, or basal cell carcinomas. Patients with breast cancers containing immunoreactive ER survived significantly longer after operation than patients whose tumor lacked immunoreactive ER. This immunoassay for ER is simpler than the binding assay and requires less time and tissue.
我们在此的目的是将一种用于检测乳腺癌中雌二醇受体（ER）的新型酶免疫测定法与一种涉及放射性标记雌二醇的标准测定法进行比较。标准结合测定法与免疫测定法之间存在显著相关性（rs = 0.945，p < 0.001，n = 100）。在子宫内膜癌中也发现了免疫反应性ER，但在肺癌、恶性黑色素瘤或基底细胞癌中未发现。含有免疫反应性ER的乳腺癌患者术后存活时间明显长于肿瘤缺乏免疫反应性ER的患者。这种ER免疫测定法比结合测定法更简单，所需时间和组织更少。
